AI Verdict
RNA has stronger fundamentals based on our AI analysis.
RNAZ vs RNA Fundamental Comparison
| Metric | RNAZ | RNA |
|---|---|---|
| Revenue | N/A | N/A |
| Net Income | $-21.2M | N/A |
| Net Margin | N/A | N/A |
| ROE | -1,488.0% | N/A |
| ROA | -406.0% | N/A |
| Current Ratio | 1.60x | N/A |
| Debt/Equity | 1.57x | N/A |
| EPS | $-34.49 | N/A |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RNAZ vs RNA: Frequently Asked Questions
Is RNAZ or RNA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RNA has stronger fundamentals. RNAZ is rated STRONG SELL (88% confidence) while RNA is rated SELL (20% confidence). This is not investment advice.
How does RNAZ compare to RNA fundamentally?
Transcode Therapeutics, Inc. has ROE of -1,488.0% vs Atrium Therapeutics, Inc.'s N/A. Net margins are N/A vs N/A respectively.
Which stock pays higher dividends, RNAZ or RNA?
RNAZ has a dividend yield of N/A or no dividend while RNA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RNAZ or RNA for long term?
For long-term investing, consider that RNAZ has STRONG SELL rating with 88% confidence, while RNA has SELL rating with 20% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RNAZ vs RNA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RNAZ vs RNA, the AI consensus favors RNA based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.